Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease

• Published in: Journal of the American College of Cardiology 2001-06, Vol.37 (7), p.1871-1876
• Main Authors: Inoue, Teruo, Uchida, Toshihiko, Kamishirado, Hirotoshi, Takayanagi, Kan, Morooka, Shigenori
• Format: Article
• Language: English
• Subjects: Antibodies - blood; Biological and medical sciences; Cardiology. Vascular system; Coronary Artery Disease - blood; Coronary Artery Disease - diagnostic imaging; Coronary Artery Disease - metabolism; Coronary heart disease; Disease Progression; Female; Heart; Humans; Lipoproteins, LDL - immunology; Lipoproteins, LDL - metabolism; Male; Medical sciences; Middle Aged; Oxidation-Reduction; Predictive Value of Tests; Prognosis; Radiography; Remission, Spontaneous
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/S0735-1097(01)01228-1

OBJECTIVES This study aimed to elucidate whether an antibody against oxidized low density lipoprotein (anti-Ox-LDL) could predict short-term coronary artery atherosclerotic lesion progression. BACKGROUND It is still controversial whether higher levels of the anti-Ox-LDL titer are associated with atherosclerotic coronary artery disease. METHODS In 52 patients undergoing coronary angioplasty and six-month follow-up angiography, we performed quantitative coronary angiographic analysis of a lesion on a branch away from the intervention site vessel and assessed lesion progression or regression using the Progression-Regression score calculated as the baseline minimal lumen diameter minus the follow-up minimal lumen diameter. The serum anti-Ox-LDL titer was measured using an enzyme-linked immunosorbent assay method just before the initial angiography in all patients. RESULTS The anti-Ox-LDL titer was 16.6 ± 1.5 AcU/ml in the progression group (Progression-Regression score >0.15 mm; n = 20), which was significantly higher (p < 0.001) than the value of 9.5 ± 1.2 in the regression group (≤−0.15 mm; n = 14) and also higher (p < 0.01) than the value of 11.4 ± 1.3 in the no-change group (−0.15 to 0.15 mm; n = 18). The Progression-Regression score was correlated with the antibody titer in all patients (r = 0.56, p < 0.001). Multiple regression analysis showed that the Progression-Regression score was independently correlated with the antibody titer (r = 0.44, p < 0.01) as well as lipoprotein (a) (r = 0.33, p < 0.05). CONCLUSIONS Anti-Ox-LDL may be an independent predictor of coronary atherosclerotic lesion progression in the short term.